Efficient manufacturing and engraftment of CCR5gene-edited HSPCs following busulfan conditioning in nonhuman primates

By sjmartinez • August 14, 2023

Murray J, Einhaus T, Venkataraman R, Radtke S, Zhen A, Carrillo MA, Kitchen SG, Peterson CW, Kiem HP. Efficient manufacturing and engraftment of CCR5 gene-edited HSPCs following busulfan conditioning in nonhuman primates. Mol Ther Methods Clin Dev. 2023 Jul 18;30:276-287. doi: 10.1016/j.omtm.2023.07.006. PMID: 37575091; PMCID: PMC10415663.

Tags: autologous transplant, cell therapy, conditioning, CRISPR, Gene therapy, Hematology/Oncology, hematopoietic stem cells, nonhuman primate, Publications

Related Posts

CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions

Patil T, Lin JJ, Cheema PK, Carrizosa DR, Burkard ME, Elamin YY, Desai J, Patel JD, Nagasaka M, Reckamp KL, Waqar SN, Bauman JR, Schram[...]

Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Hwang S, Shin DJ, Kang B, Kang H, Lee SH, Kim JS, Joung JG, Jain S, Olsen S, Becker L, Finn RS, Llovet JM, Kim[...]

KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy

Rugo HS, Cescon DW, Robson ME, Im SA, Dalenc F, Yañez Ruiz E, Reyes-Cosmelli F, Walshe JM, Im YH, Kulyk S, Dudnichenko O, Llinás-Quintero N,[...]